JACC:异丙醇乙酯可以减少高血脂患者缺血性事件的发生风险

2019-06-21 不详 MedSci原创

既往研究显示,异丙醇乙酯可以明显减少甘油三酯升高患者首次缺血性事件的发生,包括心源性死亡事件。但其对后续缺血事件风险的影响尚不清楚。REDUCE-IT临床试验将8179名甘油三酯升高的接受他汀类药物治疗的患者随机分成异丙醇乙酯治疗组(4g/天)和安慰剂组。主要终点事件包括首发和后续的总体不良事件(心源性死亡、非致死性心梗、非致死性卒中、冠脉血运重建和因不稳定心绞痛住院)。经过平均4.9年时间的随访

既往研究显示,异丙醇乙酯可以明显减少甘油三酯升高患者首次缺血性事件的发生,包括心源性死亡事件。但其对后续缺血事件风险的影响尚不清楚。

REDUCE-IT临床试验将8179名甘油三酯升高的接受他汀类药物治疗的患者随机分成异丙醇乙酯治疗组(4g/天)和安慰剂组。主要终点事件包括首发和后续的总体不良事件(心源性死亡、非致死性心梗、非致死性卒中、冠脉血运重建和因不稳定心绞痛住院)。经过平均4.9年时间的随访,有1606个首发主要终点事件发生,1303个后续主要终点事件发生,总体上来看,异丙醇乙酯可以减少总体主要终点事件的发生(RR: 0.70; 95% cl: 0.62-0.78; p < 0.0001),同时,也可减少各个终点事件的发生风险。

研究结果显示,在甘油三酯升高的接受他汀类药物治疗的患者中,异丙醇乙酯可以减少患者首发、后续及总体的缺血性事件发生风险。

原始出处:

本文系梅斯医学(MedSci)原创编译整理,转载需授权

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1893182, encodeId=f21e1893182ec, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Thu Nov 21 21:34:00 CST 2019, time=2019-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854413, encodeId=4a09185441370, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Mon Aug 19 09:34:00 CST 2019, time=2019-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326237, encodeId=33c0132623ef4, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sun Jun 23 00:34:00 CST 2019, time=2019-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1362679, encodeId=f92513626e92c, content=<a href='/topic/show?id=707e102e36af' target=_blank style='color:#2F92EE;'>#高血脂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102736, encryptionId=707e102e36af, topicName=高血脂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ced3193, createdName=freve, createdTime=Sun Jun 23 00:34:00 CST 2019, time=2019-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=368114, encodeId=c2d036811479, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=afa32365525, createdName=122e052cm96暂无昵称, createdTime=Fri Jun 21 13:04:45 CST 2019, time=2019-06-21, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1893182, encodeId=f21e1893182ec, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Thu Nov 21 21:34:00 CST 2019, time=2019-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854413, encodeId=4a09185441370, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Mon Aug 19 09:34:00 CST 2019, time=2019-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326237, encodeId=33c0132623ef4, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sun Jun 23 00:34:00 CST 2019, time=2019-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1362679, encodeId=f92513626e92c, content=<a href='/topic/show?id=707e102e36af' target=_blank style='color:#2F92EE;'>#高血脂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102736, encryptionId=707e102e36af, topicName=高血脂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ced3193, createdName=freve, createdTime=Sun Jun 23 00:34:00 CST 2019, time=2019-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=368114, encodeId=c2d036811479, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=afa32365525, createdName=122e052cm96暂无昵称, createdTime=Fri Jun 21 13:04:45 CST 2019, time=2019-06-21, status=1, ipAttribution=)]
    2019-08-19 hbwxf
  3. [GetPortalCommentsPageByObjectIdResponse(id=1893182, encodeId=f21e1893182ec, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Thu Nov 21 21:34:00 CST 2019, time=2019-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854413, encodeId=4a09185441370, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Mon Aug 19 09:34:00 CST 2019, time=2019-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326237, encodeId=33c0132623ef4, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sun Jun 23 00:34:00 CST 2019, time=2019-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1362679, encodeId=f92513626e92c, content=<a href='/topic/show?id=707e102e36af' target=_blank style='color:#2F92EE;'>#高血脂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102736, encryptionId=707e102e36af, topicName=高血脂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ced3193, createdName=freve, createdTime=Sun Jun 23 00:34:00 CST 2019, time=2019-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=368114, encodeId=c2d036811479, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=afa32365525, createdName=122e052cm96暂无昵称, createdTime=Fri Jun 21 13:04:45 CST 2019, time=2019-06-21, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1893182, encodeId=f21e1893182ec, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Thu Nov 21 21:34:00 CST 2019, time=2019-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854413, encodeId=4a09185441370, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Mon Aug 19 09:34:00 CST 2019, time=2019-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326237, encodeId=33c0132623ef4, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sun Jun 23 00:34:00 CST 2019, time=2019-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1362679, encodeId=f92513626e92c, content=<a href='/topic/show?id=707e102e36af' target=_blank style='color:#2F92EE;'>#高血脂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102736, encryptionId=707e102e36af, topicName=高血脂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ced3193, createdName=freve, createdTime=Sun Jun 23 00:34:00 CST 2019, time=2019-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=368114, encodeId=c2d036811479, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=afa32365525, createdName=122e052cm96暂无昵称, createdTime=Fri Jun 21 13:04:45 CST 2019, time=2019-06-21, status=1, ipAttribution=)]
    2019-06-23 freve
  5. [GetPortalCommentsPageByObjectIdResponse(id=1893182, encodeId=f21e1893182ec, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Thu Nov 21 21:34:00 CST 2019, time=2019-11-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854413, encodeId=4a09185441370, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Mon Aug 19 09:34:00 CST 2019, time=2019-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326237, encodeId=33c0132623ef4, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sun Jun 23 00:34:00 CST 2019, time=2019-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1362679, encodeId=f92513626e92c, content=<a href='/topic/show?id=707e102e36af' target=_blank style='color:#2F92EE;'>#高血脂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102736, encryptionId=707e102e36af, topicName=高血脂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ced3193, createdName=freve, createdTime=Sun Jun 23 00:34:00 CST 2019, time=2019-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=368114, encodeId=c2d036811479, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=afa32365525, createdName=122e052cm96暂无昵称, createdTime=Fri Jun 21 13:04:45 CST 2019, time=2019-06-21, status=1, ipAttribution=)]
    2019-06-21 122e052cm96暂无昵称

    0

相关资讯

JACC:一种简单且辨别力强的术前心血管评估新指标

目前,用于术前心血管评估的指标中,部分辨别力强,但操作复杂;一些简单指标辨别力又较弱。鉴于此,Habib A. Dakik等研究者开展的一项研究旨在前瞻性得出并验证一种简单且辨别力强的评估指标,该指标可对接受非心脏手术患者的心血管风险进行分层。

elife:三大**医学期刊随机对照试验分析:近400项研究结论被推翻,心血管疾病常见

据一项针对三大主流期刊——美国医学协会杂志(JAMA)、柳叶刀(Lancet)和新英格兰医学杂志(NEJM)上15年来3017项随机对照试验的分析显示,近400种公认的医疗措施研究有效,但后来结论反而被推翻。

Sleep告诉你,不同年龄该怎么午睡?

春困、夏乏、秋无力、冬眠,多少人开启了循环模式?

患者“不听话”,JAHA研究数据吓吓他

患者依从性不好,心血管事件风险高3倍。

ADA 2019:肾脏与心血管并发症有何关系?如何影响糖尿病治疗和预后?

编者按:众所周知,糖尿病患者中肾脏及心血管并发症常伴发存在。那么,肾脏疾病与心血管并发症之间到底存在着怎样的相互关系?相关研究取得了哪些重大进展?针对糖尿病患者,我们应如何进行心肾并发症的有效防治?在第79届ADA科学年会上,Edwin Bierman奖得主——丹麦哥本哈根大学Peter Rossing教授就上述临床实践中大家所关心的现实问题进行了专题解析。

一酒抵十烟?!又抽烟又喝酒,大罗神仙难相救!

五十步笑百步,说再多也不算数。